Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...

Curevo is taking on biotech giant GlaxoSmithKline, which sells Shingrix, its shingles vaccine approved in 2017. Medicxi, a European biotech-focused firm, led the Series B round. Other backers ...

The recombinant zoster vaccine is effective in preventing herpes zoster in adults aged 50 years or older with rheumatoid ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

Vaccination against shingles may reduce dementia risk, suggesting viral infections play a crucial role in Alzheimer’s disease ...

Two conferences were held in Hanoi and Ho Chi Minh City in early March to discuss shingles in comorbid patients.

Former Chair of GSK’s vaccine business and Chief Scientific ... B round to advance development of amezosvatein, its vaccine for shingles. Leading the round is new investor Medicxi, a European ...